Search

Your search keyword '"Caminal-Montero, L."' showing total 7 results
Start Over Author "Caminal-Montero, L." Publication Year Range This year
7 results on '"Caminal-Montero, L."'

1. POS1007 THE INVOLVEMENT OF THE C5 AND C5AR1 GENES IN THE PATHOGENESIS OF IgAV

Author

Batista-Liz, J. C., primary, Calvo-Río, V., additional, Sebastián Mora-Gil, M., additional, Sevilla-Pérez, B., additional, Callejas, J. L., additional, Leonardo, M. T., additional, Peñalba, A., additional, Cabero, M. J., additional, Narváez, J., additional, Martín-Penagos, L., additional, Belmar-Vega, L., additional, Gomez-Fernandez, C., additional, Caminal-Montero, L., additional, Collado, P., additional, Quiroga Colina, P., additional, Vicente-Rabaneda, E., additional, Rubio-Romero, E., additional, León Luque, M., additional, Blanco-Madrigal, J. M., additional, Galíndez-Agirregoikoa, E., additional, Castañeda, S., additional, Blanco, R., additional, Pulito-Cueto, V., additional, and López-Mejías, R., additional

Published
2024
Full Text
View/download PDF

2. AB1240 NLRP3 AND CASP1 GENES AS DISCRIMINATORY MARKERS BETWEEN IGA VASCULITIS AND IGA NEPHROPATHY?

Author

Batista-Liz, J. C., primary, Sebastián Mora-Gil, M., additional, Gabrie, L., additional, Gálvez-Sánchez, R., additional, Leonardo, M. T., additional, Peñalba, A., additional, Sevilla-Pérez, B., additional, Callejas, J. L., additional, Caminal-Montero, L., additional, Narváez, J., additional, Martín-Penagos, L., additional, Belmar-Vega, L., additional, Collado, P., additional, Fernández-Nebro, A., additional, Díaz-Cordoves, G., additional, Quiroga Colina, P., additional, Vicente-Rabaneda, E., additional, Cigarrán, S., additional, Calviño, J., additional, Cobelo, C., additional, Rubio-Romero, E., additional, León Luque, M., additional, Blanco-Madrigal, J. M., additional, Galíndez-Agirregoikoa, E., additional, Castañeda, S., additional, Blanco, R., additional, Pulito-Cueto, V., additional, and López-Mejías, R., additional

Published
2024
Full Text
View/download PDF

4. POS0256 THE FIRST METHYLOME PROFILING STUDY OF B-CELLS IN IGA VASCULITIS REVEALED POTENTIAL BIOMARKERS OF DISEASE SUSCEPTIBILITY

Author

López-Mejías, R., primary, Pulito-Cueto, V., additional, Fernández Rengel, I., additional, Terron Camero, L. C., additional, Batista-Liz, J., additional, Sebastián Mora-Gil, M., additional, Leonardo, M. T., additional, Peñalba, A., additional, Martín-Penagos, L., additional, Belmar-Vega, L., additional, Gomez-Fernandez, C., additional, Gabrie, L., additional, Gálvez-Sánchez, R., additional, Caminal-Montero, L., additional, Turrión, A. I., additional, Quiroga Colina, P., additional, Vicente-Rabaneda, E., additional, Sevilla-Pérez, B., additional, Callejas, J. L., additional, Andrés-León, E., additional, Martin, J., additional, Márquez, A., additional, Castañeda, S., additional, and Blanco, R., additional

Published
2024
Full Text
View/download PDF

5. Circulating levels of Low Density Granulocytes and cell-free DNA as predictors of cardiovascular disease and bone deterioration in SLE patients.

Author

Suárez A, Tobío-Parada U, Rodríguez-Carrio J, Martínez-Zapico A, Pérez-Álvarez AI, Suárez-Díaz S, Caminal-Montero L, and López P

Abstract

The present work evaluates the predictive value of low-density-granulocytes (LDG) for the development of cardiovascular disease (CVD) and/or bone deterioration (BD) in a six-year prospective study in Systemic Lupus Erythematosus (SLE). Considering the high SLE-LDG capacity to form Neutrophil Extracellular Traps (NETs), circulating levels of total cell-free DNA (cirDNA) and relative amounts of mitochondrial and nuclear DNA (mtDNA and nDNA, respectively) were tested as LDG-associated biomarkers to identify SLE patients at risk of CVD and BD. To this end, the frequency of total blood LDGs, as well as the CD16negCD14neg (nLDG) and CD16posCD14low (pLDG) subsets, was quantified by flow cytometry in 33 controls and 144 SLE patients. Total cirDNA and relative amounts of mitochondrial (mtDNA) and nuclear (nDNA) cell-free DNA were measured by fluorometry or qPCR in plasma from a subgroup of 117 patients and 23 controls at enrolment. Our findings showed increased blood levels of SLE-nLDGs at enrolment associated with prospective CVD development (pCVD) and the presence of BD, thus revealing LDG expansion as a predictor of both comorbidities in SLE progression. The amounts of the different types of circulating DNA analysed were increased in patients, especially those presenting traditional CV-risk factors or subclinical atheromatosis. Similar to nLDGs, the nDNA concentration could predict the development of pCVD in SLE, supporting the quantification of cirDNA levels as a surrogate marker of LDGs in clinical practice., Competing Interests: The authors declare that they have no conflict of interest., (Thieme. All rights reserved.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results